REGENXBIO Stock Forecast, Price & News

REGENXBIO (NASDAQ:RGNX) Frequently Asked Questions

Is REGENXBIO a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REGENXBIO stock.
View analyst ratings for REGENXBIO or view top-rated stocks.

How has REGENXBIO's stock been impacted by COVID-19 (Coronavirus)?

REGENXBIO's stock was trading at $32.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RGNX stock has decreased by 24.3% and is now trading at $24.91.
View which stocks have been most impacted by COVID-19.

When is REGENXBIO's next earnings date?

REGENXBIO is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for REGENXBIO.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) posted its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($1.37) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.87) by $0.50. The biotechnology company had revenue of $30.77 million for the quarter, compared to analysts' expectations of $49.35 million. REGENXBIO had a negative net margin of 228.08% and a negative trailing twelve-month return on equity of 44.70%. During the same period in the previous year, the company posted $0.23 EPS.
View REGENXBIO's earnings history.

What price target have analysts set for RGNX?

7 brokerages have issued twelve-month target prices for REGENXBIO's shares. Their forecasts range from $17.00 to $90.00. On average, they anticipate REGENXBIO's stock price to reach $54.00 in the next year. This suggests a possible upside of 116.8% from the stock's current price.
View analysts' price targets for REGENXBIO or view top-rated stocks among Wall Street analysts.

Who are REGENXBIO's key executives?

REGENXBIO's management team includes the following people:

• Kenneth T. Mills, President, Chief Executive Officer & Director
• Curran M. Simpson, SVP, Chief Operations & Technology Officer
• Vit Vasista, Chief Financial Officer & Senior Vice President
• Olivier Danos, Chief Scientific Officer & Senior Vice President
• Stephen Pakola, Chief Medical Officer & Senior Vice President

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO CEO Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among REGENXBIO's employees.

Who are some of REGENXBIO's key competitors?

Some companies that are related to REGENXBIO include Denali Therapeutics (DNLI), Abcam (ABCM), Ablynx (ABLYF), Fate Therapeutics (FATE), Kodiak Sciences (KOD), Twist Bioscience (TWST), SpringWorks Therapeutics (SWTX), BioCryst Pharmaceuticals (BCRX), Relay Therapeutics (RLAY), Adaptive Biotechnologies (ADPT), Bavarian Nordic A/S (BVNRY), Iovance Biotherapeutics (IOVA), Exscientia (EXAI), ImmunityBio (IBRX) and Kymera Therapeutics (KYMR).
View all of RGNX's competitors.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Square (SQ).

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Liberty One Investment Management LLC (0.07%), State of Alaska Department of Revenue (0.06%) and Cutler Group LP (0.00%). Company insiders that own REGENXBIO stock include Allan M Fox, Curran Simpson, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends for REGENXBIO.

Which major investors are selling REGENXBIO stock?

RGNX stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP, and State of Alaska Department of Revenue. Company insiders that have sold REGENXBIO company stock in the last year include Allan M Fox, Kenneth T Mills, Steve Pakola, and WR Stephens, Iii 2012 Trust.
View insider buying and selling activity for REGENXBIO or view top insider-selling stocks.

Which major investors are buying REGENXBIO stock?

RGNX stock was acquired by a variety of institutional investors in the last quarter, including Liberty One Investment Management LLC.
View insider buying and selling activity for REGENXBIO or or view top insider-buying stocks.

How do I buy shares of REGENXBIO?

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $24.91.

How much money does REGENXBIO make?

REGENXBIO has a market capitalization of $1.07 billion and generates $154.57 million in revenue each year. The biotechnology company earns $-111.25 million in net income (profit) each year or ($5.17) on an earnings per share basis.

How many employees does REGENXBIO have?

REGENXBIO employs 306 workers across the globe.

What is REGENXBIO's official website?

The official website for REGENXBIO is www.regenxbio.com.

Where are REGENXBIO's headquarters?

REGENXBIO is headquartered at 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850.

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at (240) 552-8181 or via email at [email protected].